Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disulfiram and Copper Gluconate in Refractory Multiple Myeloma
NCT04521335Phase 1Terminated
- Sponsor
- University of Utah
- Start
- May 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of disulfiram in multiple myeloma (MM), sponsored by University of Utah. Primary endpoint: Rate of dose limiting toxicities at 28 days. Started May 2021; status: terminated.
02
Drugs
disulfiram
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04521335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521335.